Mack Beer is a very experienced man in commercialisation and development of pharmaceuticals, devices, biotechnology, and diagnostics. He had over 25 years in the field and founded Renovia company together with Ramon Iglesias, Yolanda Lorie and MD in 2016. The company deals with lending capital funds to health care ventures.
In 2000 Mack Beer became the CEO of NASDAQ; VIAC which is a biotechnology company and specialises in preservation, collection and development of blood stem cells for the umbilical cord. Under his leadership, he grew the company from the start to rapidly growing and robust organisation it is today. The company has over 300 employees; it was later acquired by PerkinElmer in 2007.
Before becoming CEO to big organisations, Mack held different positions in his career. While CEO at ViaCell he was also serving in the board of directors at Erytec pharmaceuticals which is a public company.
In Genzyme, he was the vice president of global marketing. Here, he was in charge of the commercial launch of many products addressing many rare diseases around the globe. He also served in a marketing and sales position at Abbott Laboratories; Marc was also a member of Mass Life Science at commonwealth.
Renovia Inc. will be making new products dealing with pelvic floor disorder; the company just closed a $32 million Series B deal on Tuesday and addition of venture debt worth $10 million. The company is developing several therapeutical and diagnostic products to aid in the better treatment of pelvic floor disorders such as urinary incontinence which is common among women. Renovia had their first product in this line approved by the FDA in April.
Urinary incontinence is a rare type of pelvic floor disease that affects mostly women. Currently, over $250 million women around the world suffer from this disorder. Therefore, there is need for more awareness of this disorder and also better medication and better diagnostics.
Longwood fund, which is an investment firm that primarily focuses on health-care had invested earlier in Renovia; recently the company has joined series B round which is led by Perspective Advisers a New York-based company and Missouri-Ascension Ventures. This funding will be used for development and testing of their four new diagnostic and therapeutic products, which includes the generation of a new Leva device.
Mack Beer expressed his appreciation for the new support in the venture to better the diagnoses and treatment of pelvic floor disorders and hence save the lives of many women around the world. According to Marc, the combination of the two innovation and technology will help to develop a digital health programme that will provide customers with valuable data and information about new and available treatment options; this will help to drive understanding of this disorders and hence lower the healthcare cost in the long run. Learn more: https://www.bizjournals.com/boston/potmsearch/detail/submission/6457372/Marc_Beer